Completed PHASE1 INTERVENTIONAL 2-arm NCT01248650

Safety Study of TRK-820 for Patient With Hemodialysis (TRK-820)

A Clinical Study to Investigate Pharmacokinetics and Safety of Single-Dose TRK-820 Soft Capsule in Patient With Hemodialysis

Sponsor: SK Chemicals Co., Ltd.

Conditions Chronic Renal Failure

Interventions nalfurafine hydrochloride

Updated 7 times since 2017 Last updated: Nov 24, 2010 Started: Dec 31, 2008 Primary completion: Dec 31, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01248650, this PHASE1 trial focuses on Chronic Renal Failure and remains completed. Sponsored by SK Chemicals Co., Ltd., it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Feb 2019 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Jun 2018 — Feb 2019 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SK Chemicals Co., Ltd.
Toray Industries, Inc

Data source: SK Chemicals Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea